Fig. 4
From: Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial
Clinical and structural changes following tDCS treatment. Change in monthly migraine days depicted as difference in days between verum and sham tDCS group (A). Change in GM volume depicted as difference in percent between verum and sham tDCS group (B). Negative values represent less migraine days, respectively lower GM volume in the verum tDCS group compared to the sham tDCS group. All values are normalized to the baseline measurement